Chief Operating Officer · NovoCure Ltd (NVCR)

Wilhelmus Groenhuysen

A named executive officer of NovoCure in every fiscal year CompBrief holds from FY2016 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$6,624,282

Salary $615,000Stock awards $3,533,227

FY2021: $6,386,961

2nd of 5 named executive officers at NovoCure by FY2022 total.

5 named officers on file for NovoCure, FY2022

Wilhelmus Groenhuysen’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 19 equity grants, each cited to its filing
  • NVCR’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NovoCure’s whole pay program stands against its peers

  • NovoCure’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NVCR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2023 (DEF 14A).

Free

Get Wilhelmus Groenhuysen’s full pay file as a PDF — free

More than this page: up to 10 years of Wilhelmus’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Wilhelmus Groenhuysen compensation by year

NovoCure Summary Compensation Table · all 7 fiscal years held
In US dollars, as NovoCure reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022
Salary$600,600$600,600$600,600$600,600$611,400$615,000$615,000
Bonus$0$0$0$0$250,000$0$0
Stock awards$0$929,500$489,580$962,485$3,666,529$3,833,245$3,533,227
Option awards$5,630,025$1,195,857$1,966,162$2,202,814$1,827,243$1,914,408$2,084,406
Non-equity incentive$0$360,360$375,375$396,396$553,500$0$369,000
Pension and deferred compensation$0$0$0$0$0$0$0
All other$28,470$30,765$27,500$24,789$29,252$24,308$22,649
Total$6,259,095$3,117,082$3,459,217$4,187,084$6,937,924$6,386,961$6,624,282

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 24, 2023, accession 0001645113-23-000034, and prior-year filings. Open the filing on EDGAR.

How this page was built: the NovoCure Ltd filed document, accession 0001645113-23-000034. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2023.

$6.3M
$3.1M
$3.5M
$4.2M
$6.9M
$6.4M
$6.6M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU24,025$1,762,234—
RSU21,921$1,607,905—
PSU21,921$1,607,905—
PSU16,775$1,230,446—
RSU8,345$612,106—
RSU8,008$587,387—
PSU1,968$144,353—
RSU655$48,044—
Option23,161—$69.37
Option1,889—$84.68
Option7,664—$80.59
Option38,390—$80.59

Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2022 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 14 award rows shown.

NovoCure’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Ashley CordovaChief Financial Officer$6,842,664
Wilhelmus Groenhuysen · this pageChief Operating Officer$6,624,282
Pritesh ShahChief Commercial Officer$6,316,633
Francis LeonardPresident, CNS Cancers US$6,125,806
Asaf DanzigerChief Executive Officer$2,278,951

The full NovoCure compensation record

free company brief

This page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NovoCure proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Wilhelmus Groenhuysen's compensation dossier · One-time report. No refunds.